Primer: Taigen Biopharmaceuticals (4157 TT) - Aug 2026
Taigen is transitioning from a pure R&D entity to a commercial-stage biopharmaceutical company, anchored by its flagship antibiotic,...
84 Views
APAC Healthcare Weekly (March 8) – Sino Bio, Antengene, Takeda, Sumitomo Pharma, ABL Bio, Glenmark
Sino Bio and Anetengene stuck outlicensing deals with Sanofi and UCB, respectively. FDA accepted Takeda’s NDA for rusfertide. Sumitomo Pharma got...
548 Views
TaiGen Sold Its Furaprevir for 25x of Market Capital
Summary What's new? Taigen and HEC Pharm announced a new joint venture. HEC Pharm agrees Taigen to use its developed new drug Furaprevir...
481 Views
No more insights